Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

A Randomized, Open-label, Multiple-dose, Cross-over Dosing Study to Evaluate Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin in Healthy Adults

This study is to evaluate pharmacokinetic drug interaction between teneligliptin and empagliflozin in healthy adults.

Inclusion Criteria:

• Healthy adults between 19 and 45 years of age (both inclusive) at the screening visit
• Body mass index between 19 kg/m2 and 28 kg/m2 (both inclusive) at the screening visit
• Subjects must voluntarily decide to participate in the study and provide written informed consent to comply with study instructions

Exclusion Criteria:

• History of type 1 diabetes mellitus and/or diabetic ketoacidosis
• Severe infection, surgery, or severe trauma within 6 months prior to the screening visit
• Hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• Treatment with any investigational product or study drug in another clinical trial or bioequivalence study within 180 days prior to the screening visit
• Any laboratory test or 12-lead ECG finding based on which the subject is determined ineligible to participate in the study
• Subject determined by the principal investigator to be ineligible for study conduct for other reasons